CA 27.29 may be useful for monitoring patients with various cancers. Elevated CA 27.29 levels are associated with metastatic breast cancer and sometimes with primary breast cancer. CA 27.29 is also elevated in ovarian, liver, pancreatic and lung cancer, as well as in the nonmalignant conditions detailed in the table below. Rising levels suggest lack of therapeutic response and/or progressive disease, whereas decreasing levels suggest response to treatment and disease regression. CA 27.29 elevations in patients with a history of breast cancer and no clinical evidence of disease suggest recurrence.
$35Average competitors price
$120Pricing based on average direct to consumer pricing.
- Fasting Required: NO
- Preferred Specimen: Serum
- Reference Range(s): CA 27.29 38 U/mL
- Limitations: CA 27.29 is not intended as a screening test. Values obtained from different assay methods cannot be used interchangeably. CA 27.29 levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease.
- Turnaround Time: 3 Day
- Test Code: 29493